# ANJA J. RUETEN-BUDDE, PHD

aruetenbudde@statisticiannextdoor.com
www.statisticiannextdoor.com
Roseggerstaße 23, 8700 Leoben, Austria
Born 12.08.1990 in Bremen, Germany

## PROFESSIONAL EXPERIENCE

**Statistician Next Door, Leoben, Austria**                    *Oktober 2024 - Present*
Statistical Consultant

- Statistician Next Door offers expert statistical consulting tailored to meet the diverse needs of companies, researchers, and professionals.

- Specialize in data exploration, advanced statistical modeling, and creating clear, actionable insights.

**Career Break**                    *June 2022 - September 2024*
Planned career break due to relocation and family care-giving, and the birth of my daughter. During this time, I actively engaged in volunteer work. This included:

- Tutoring students in German and math

- Assisting in a German class for women

- Conversational German practice with refuges in an organized setting

**Erasmus Medical Center, Rotterdam, the Netherlands**                    *June 2020 - May 2022*
Postdoc in Biostatistics

- As part of the convergence of health and technology project between Erasmus University, Erasmus Medical Center and Delft University of Technology, the aim of this project was to apply and develop machine learning algorithms to improve patient care.

- My position included providing statistical consulting services to medical researchers from the Erasmus Medical Center.

## EDUCATION

**Leiden University, Leiden, the Netherlands**                    *February 2016 - March 2020*
PhD in Statistics

- Personalised medicine for multiple outcomes : methods and application. PhD diss., Leiden University, 2020.

- The primary interest has been the study and prediction of survival for soft tissue sarcoma patients. The Personalised Sarcoma Care (PERSARC) mobile application has been a research output. Another interest was the development and study of new methods in survival analysis.

- Additionally, I provided statistical consulting services to researchers from the Leiden University Medical Center.

- Conferences I participated and presented in: useR!2016 (USA), IBS Channel Network Conference 2017 (Hasselt). I presented my research at PTA 2016 (London), ISCB 2016 (Birmingham), Stochastics meeting 2016 (Lunteren), SAFJR 2017 (Leicester), EMS 2017 (Helsinki), NMC 2018 (Veldhoven), SMDM 2018 (Leiden), JSM 2018 (Vancouver), IBS Channel Network Conference 2019 (Harpenden), SAFJR 2019 (Copenhagen). I co-organized SAFJR 2018 (Leiden).

**Leiden University, Leiden, the Netherlands**  *September 2013 - December 2015*
Master of Science
Subject: Statistical Science for the Life and Behavioural Sciences

**Bremen University, Bremen, Germany**  *October 2009 - March 2013*
Bachelor of Science
Major subject: Mathematics, Minor: Computer Science

## SKILLS & STRENGTHS

| | |
|---|---|
| **Software** | R (proficient), Python (familiar), SPSS (familiar), MS Office (proficient), Latex (proficient) |
| **Languages** | German (native), English (fluent), Spanish (fluent), Dutch (fluent). |
| **Personal Traits** | Patient, strong communication skills. |

## TEACHING EXPERIENCE

**Survival Analysis:** Survival Analysis course for the Statistical Science Master at Leiden University (teaching assistant 2016-2020, lecturer 2019) and at Leiden University Medical Center (teaching assistant 2017).

**Statistics:** Statistics course at Leiden University College (lecturer 2017-2019).

**Advanced Computing:** Advanced Computing course for the Statistical Science Master at Leiden University (teaching assistant 2016).

## EXTRA-CURRICULAR

Published knitting pattern "Spherical fractal scarf" together with Niels Langeveld in 2019 (4000+ unique downloads).

Co-organized the Survival Analysis for Junior Researchers (SAFJR) conference 2018 in Leiden.

Attended a workshop on extended use of regression models for new epidemiologic designs and analyses by prof. Marie Reilly and prof. Chueng Seng Tan (Ponte di Legno 2018).

Assisted in the workshop "Make your own fractal" at the Leiden Science family day 2018.

## PUBLICATIONS

1. M. de Bakker, T. B. Petersen, **A. J. Rueten-Budde**, et al. Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure. Eur Heart J Digit Health. 2023; 4(6):444–454. DOI: 10.1093/ehjdh/ztad056

2. S.T. Mulder, A.H. Omidvari, **A. J. Rueten-Budde**, et al. Dynamic digital twin: diagnosis, treatment, prediction, and prevention of disease during the life course. J Med Internet Res. 2022; 24:e35675. DOI: 10.2196/35675

3. I. Acem, W. J. van Houdt, D. J. Grünhagen, W. T.A. van der Graaf, **A. J. Rueten-Budde**, et al. The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using persarc. Eur J Cancer. 2022; 165:71–80. DOI: 10.1016/j.ejca.2022.01.013

4. R.E. Evenhuis, I. Acem, **A. J. Rueten-Budde**, et al. Survival analysis of 3 different age groups and prognostic factors among 402 patients with skeletal high-grade osteosarcoma. Real world data from a single tertiary sarcoma center. Cancers. 2021; 13(3):486. DOI: 10.3390/cancers13030486

5. **A. J. Rueten-Budde**, et al. External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. J Surg Oncol. 2021; 123(4):1050–1056. DOI: 10.1002/jso.26337

6. **A. J. Rueten-Budde**, et al. Dynamic prediction of overall survival for patients with ewing sarcoma. BMJ Open. 2020; 10(10): e036376. DOI: 10.1136/bmjopen-2019-036376

7. I. Acem, C. Verhoef, **A. J. Rueten-Budde**, et al. Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. Eur J Cancer. 2020; 141:128–136. DOI: 10.1016/j.ejca.2020.09.021

8. E. Schutgens, P. Picci, D. Baumhoer, R. Pollock, J. Bovee, P. Hogendoorn, P. Dijkstra, **A. J. Rueten-Budde**, et al. Surgical outcome and oncological survival of osteofibrous dysplasia-like- and classic adamantinoma: an international multicenter study of 318 cases. J Bone Joint Surg Am. 2020; 102(19):1703–1713. DOI: 10.2106/JBJS.19.01056

9. **A. J. Rueten-Budde**, et al. Individual risk evaluation for local recurrence and distant metastasis in ewing sarcoma: a multistate model. Pediatr Blood Cancer. 2019; 66(11):e27943. DOI: 10.1002/pbc.27943

10. M. J. L. Mastboom, E. Palmerini, F. G. M. Verspoor, **A. J. Rueten-Budde**, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019; 20(6):877–886. DOI: 10.1016/S1470-2045(19)30100-7

11. M. Mastboom, E.Staals, F.Verspoor, **A. J. Rueten-Budde**, et al. Surgical treatment of localized-type tenosynovial giant cell tumours of large joints. J Bone Joint Surg. 2019; 101(14):1309–1318. DOI: 10.2106/JBJS.18.01147

12. S. Bosma, C. Lancia, **A. J. Rueten-Budde**, et al. Easy-to-use clinical tool for survival estimation in ewing sarcoma at diagnosis and after surgery. Sci Rep. 2019; 9(1):11000. DOI: 10.1038/s41598-019-46721-8

13. **A. J. Rueten-Budde**, H. Putter, and M. Fiocco. Investigating hospital heterogeneity with a competing risks frailty model. Stat Med. 2018; 38(2):269–288. DOI: 10.1002/sim.8002

14. **A. J. Rueten-Budde**, et al. Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol. 2018; 27(4):695–701. DOI: 10.1016/j.suronc.2018.09.003

15. V. van Praag, **A. J. Rueten-Budde**, et al. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol. 2018; 27(3):402–408. DOI: 10.1016/j.suronc.2018.05.009

16. **A. J. Rueten-Budde**, et al. Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model. BMJ Open. 2017 7(2):e012930. DOI: 10.1136/bmjopen-2016-012930

17. **A. J. Rueten-Budde**, et al. A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: personalised sarcoma care (persarc). Eur J Cancer. 2017; 83:313–323. DOI: 10.1016/j.ejca.2017.06.032